Clinical trials: Probable Alzheimer's Disease
Alzheimer's Disease
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a…
- Trial name
- CARE (NCT00731224)
- Testing
- Rivastigmine transdermal patch
- Where
- 40 sites in Australia, Malaysia and 3 more
- Volunteers
- 380 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects with Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers.
- Trial name
- ALZ201 (NCT00785759)
- Testing
- AH110690 (18F) Injection
- Where
- Norway
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Alzheimer's Disease
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
- Trial name
- NCT00051909
- Testing
- LY451395
- Where
- 9 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Positron-Emission Tomography, Alzheimer's Disease
Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8101 (ZK 6032924) in patients with Alzheimer's Disease compared to healthy volunteers.
- Trial name
- NCT01035164
- Testing
- F-18 FEDAA1106 (BAY85-8101)
- Where
- 3 sites in Netherlands, Sweden
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease
Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)
The goal of this clinical trial is to learn if using large-coil (or "deep") repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus and surrounding areas is feasible, tolerable, and potentially efficacious for…
- Conditions
- Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease
- Trial name
- PROMIS-AD (NCT06597942)
- Testing
- TMS
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, Los Angeles
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer's Disease
Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
The purpose of this study is to investigate the effect of the rapidly acting intranasal insulin derivative (glulisine) on memory and cognition in 12 patients suffering from mild-moderate Alzheimer's Disease (AD) using a…
- Trial name
- NCT01436045
- Testing
- Insulin glulisine, Saline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- HealthPartners Institute
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236431
- Testing
- Galantamine hydrobromide
- Volunteers
- 1,063 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
Tricaprilin in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.
- Trial name
- NCT00142805
- Testing
- Tricaprilin
- Where
- 25 sites in United States
- Volunteers
- 152 people
- Sponsor
- Cerecin
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease.
- Trial name
- NCT02503501
- Testing
- Insulin glulisine
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- HealthPartners Institute
Alzheimer Disease
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's…
- Trial name
- NCT00414622
- Testing
- DMXB-A
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- CoMentis
Healthy Volunteers, Alzheimer Disease
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
- Trial name
- NCT03545789
- Testing
- [18F]MNI-958
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Alzheimer Disease
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
- Trial name
- NCT03671889
- Testing
- Blood Brain Barrier (BBB) Disruption
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- InSightec
Alzheimer's Disease, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Trial name
- NCT01073228
- Testing
- EVP-6124
- Where
- 54 sites in United States, Romania and 3 more
- Volunteers
- 409 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
The goal of this research study is to evaluate, in the open-label extension phase, the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease
- Trial name
- NCT00219232
- Testing
- Rivastigmine Transdermal Patch
- Volunteers
- 868 people
- Sponsor
- Novartis
Diagnostic Imaging
Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY1006578 for investigation of diagnostic potential in probable Alzheimer Disease patients versus healthy volunteers and radiation dosimetry in healthy volunteers.
- Trial name
- NCT01153607
- Testing
- BAY1006578
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease, Dementia, Alzheimer Type
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
- Trial name
- NCT00099242
- Testing
- rivastigmine transdermal patch
- Where
- 75 sites in United States, Chile and 19 more
- Volunteers
- 1,040 people
- Sponsor
- Novartis Pharmaceuticals